Last reviewed · How we verify

Cultivation of Limbal epithelial cells into a graft

Massachusetts Eye and Ear Infirmary · Phase 1 active Biologic Quality 20/100

Cultivation of Limbal epithelial cells into a graft is a Biologic drug developed by Massachusetts Eye and Ear Infirmary. It is currently in Phase 1 development.

At a glance

Generic nameCultivation of Limbal epithelial cells into a graft
SponsorMassachusetts Eye and Ear Infirmary
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cultivation of Limbal epithelial cells into a graft

What is Cultivation of Limbal epithelial cells into a graft?

Cultivation of Limbal epithelial cells into a graft is a Biologic drug developed by Massachusetts Eye and Ear Infirmary.

Who makes Cultivation of Limbal epithelial cells into a graft?

Cultivation of Limbal epithelial cells into a graft is developed by Massachusetts Eye and Ear Infirmary (see full Massachusetts Eye and Ear Infirmary pipeline at /company/massachusetts-eye-and-ear-infirmary).

What development phase is Cultivation of Limbal epithelial cells into a graft in?

Cultivation of Limbal epithelial cells into a graft is in Phase 1.

What are the side effects of Cultivation of Limbal epithelial cells into a graft?

Common side effects of Cultivation of Limbal epithelial cells into a graft include Corneal Epithelium Defect, Subconjunctival Hemorrhage, Conjunctival Hyperemia, Eye Pain, Eye Tearing, Corneal Bleeding.

Related